Influence of irritable bowel syndrome on treatment outcome in gastroesophageal reflux disease

Figure 1 Flowchart of patient disposition. n: Number of patients; ITT: Intention-to-treat.

Figure 2 Subgroups of gastroesophageal reflux disease patients according to esophagitis and irritable bowel syndrome-like symptoms. Percentages do not equal 100% due to missing values. ^aP = 0.0015, irritable bowel syndrome (IBS)-like +: patients with non-erosive reflux disease (NERD) vs patients with erosive (ERD). n: Number of patients; GERD: Gastroesophageal reflux disease.

Figure 3 Response rates for gastroesophageal reflux disease/erosive/non-erosive reflux disease patients with or without irritable bowel syndrome-like symptoms after 4 and 8 wk of treatment with pantoprazole. ^aP < 0.0001 irritable bowel syndrome (IBS)-like + vs IBS-like - in patients with gastroesophageal reflux disease (GERD) after 4 wk; ^bP < 0.0001 IBS-like + vs IBS-like - in patients with GERD after 8 wk, ^cP < 0.0001 IBS-like + vs IBS-like - in patients with erosive reflux disease (ERD) after 4 wk, ^dP = 0.0339 IBS-like + vs IBS-like - in patients with ERD after 8 wk, ^eP = 0.0088 IBS-like + vs IBS-like - in patients with non-erosive reflux disease (NERD) after 8 wk.

Figure 4 Symptom scores for “acid complaints” and “lower abdominal complaints” in erosive and non-erosive reflux disease patients with and without IBS-like symptoms at baseline. ^aP < 0.0001 irritable bowel syndrome (IBS)-like + vs IBS-like - in patients with erosive reflux disease (ERD) at baseline, ^bP < 0.0001 IBS-like + vs IBS-like - in patients with non-erosive reflux disease (NERD) at baseline.